An Opportunity Missed: Biosimilars in the United States

被引：6

作者：

Goll, Guro L. ^{[1
]}

Kvien, Tore K. ^{[1
]}

机构：

[1] Diakonhjemmet Hosp, Oslo, Norway

来源：

ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷 / 07期

关键词：

DOUBLE-BLIND; ORIGINATOR INFLIXIMAB; INNOVATOR INFLIXIMAB; PARALLEL-GROUP; CT-P13; ARTHRITIS; EFFICACY; SAFETY; SWITCH;

D O I：

10.1002/art.41280

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1046 / 1048

页数：3

共 21 条

[1] Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010 [J].

Aga, Anna-Birgitte ;

Lie, Elisabeth ;

Uhlig, Till ;

Olsen, Inge Christoffer ;

Wierod, Ada ;

Kalstad, Synove ;

Rodevand, Erik ;

Mikkelsen, Knut ;

Kvien, Tore K. ;

Haavardsholm, Espen A. .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) :381-388

[2]

Baker JF, ARTHRITIS RHEUMATOL, DOI [10.1002/art.41277/abstract, DOI 10.1002/ART.41277/ABSTRACT]

[3] Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis [J].

Glintborg, Bente ;

Ibsen, Rikke ;

Bilbo, Rebecca Elisabeth Qwist ;

Hetland, Merete Lund ;

Kjellberg, Jakob .

RMD OPEN, 2019, 5 (02)

[4] To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry [J].

Glintborg, Bente ;

Loft, Anne Gitte ;

Omerovic, Emina ;

Hendricks, Oliver ;

Linauskas, Asta ;

Espesen, Jakob ;

Danebod, Kamilla ;

Jensen, Dorte Vendelbo ;

Nordin, Henrik ;

Dalgaard, Emil Barner ;

Chrysidis, Stavros ;

Kristensen, Salome ;

Raun, Johnny Lillelund ;

Lindegaard, Hanne ;

Manilo, Natalia ;

Jakobsen, Susanne Hojmark ;

Hansen, Inger Marie Jensen ;

Pedersen, Dorte Dalsgaard ;

Sorensen, Inge Juul ;

Andersen, Lis Smedegaard ;

Grydehoj, Jolanta ;

Mehnert, Frank ;

Krogh, Niels Steen ;

Hetland, Merete Lund .

ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (02) :192-200

[5] A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry [J].

Glintborg, Bente ;

Sorensen, Inge Juul ;

Loft, Anne Gitte ;

Lindegaard, Hanne ;

Linauskas, Asta ;

Hendricks, Oliver ;

Hansen, Inger Marie Jensen ;

Jensen, Dorte Vendelbo ;

Manilo, Natalia ;

Espesen, Jakob ;

Klarlund, Mette ;

Grydehoj, Jolanta ;

Dieperink, Sabine Sparre ;

Kristensen, Salome ;

Olsen, Jimmi Sloth ;

Nordin, Henrik ;

Chrysidis, Stavros ;

Pedersen, Dorte Dalsgaard ;

Sorensen, Michael Veedfald ;

Andersen, Lis Smedegaard ;

Gron, Kathrine Lederballe ;

Krogh, Niels Steen ;

Pedersen, Lars ;

Hetland, Merete Lund .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) :1426-1431

[6] Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial [J].

Goll, G. L. ;

Jorgensen, K. K. ;

Sexton, J. ;

Olsen, I. C. ;

Bolstad, N. ;

Haavardsholm, E. A. ;

Lundin, K. E. A. ;

Tveit, K. S. ;

Lorentzen, M. ;

Berset, I. P. ;

Fevang, B. T. S. ;

Kalstad, S. ;

Ryggen, K. ;

Warren, D. J. ;

Klaasen, R. A. ;

Asak, O. ;

Baigh, S. ;

Blomgren, I. M. ;

Brenna, O. ;

Bruun, T. J. ;

Dvergsnes, K. ;

Frigstad, S. O. ;

Hansen, I. M. ;

Hatten, I. S. H. ;

Huppertz-Hauss, G. ;

Henriksen, M. ;

Hoie, S. S. ;

Krogh, J. ;

Midtgard, I. P. ;

Mielnik, P. ;

Moum, B. ;

Noraberg, G. ;

Poyan, A. ;

Prestegard, U. ;

Rashid, H. U. ;

Strand, E. K. ;

Skjetne, K. ;

Seeberg, K. A. ;

Torp, R. ;

Ystrom, C. M. ;

Vold, C. ;

Zettel, C. C. ;

Waksvik, K. ;

Gulbrandsen, B. ;

Hagfors, J. ;

Mork, C. ;

Jahnsen, J. ;

Kvien, T. K. .

JOURNAL OF INTERNAL MEDICINE, 2019, 285 (06) :653-669

[7] Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial [J].

Jorgensen, Kristin K. ;

Olsen, Inge C. ;

Goll, Guro L. ;

Lorentzen, Merete ;

Bolstad, Nils ;

Haavardsholm, Espen A. ;

Lundin, Knut E. A. ;

Mork, Cato ;

Jahnsen, Jorgen ;

Kvien, Tore K. .

LANCET, 2017, 389 (10086) :2304-2316

[8] Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases [J].

Kay, Jonathan ;

Schoels, Monika M. ;

Doerner, Thomas ;

Emery, Paul ;

Kvien, Tore K. ;

Smolen, Josef S. ;

Breedveld, Ferdinand C. .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (02) :165-174

[9]

OECDiLibrary, 2020, HLTH STAT LIF EXP BI

[10]

OECDiLibrary, 2020, HLTH STAT INF MORT R

← 1 2 3 →